Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)

References

• Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001; 358: 2026–33
   PubMed Web of Science ®Google Scholar
• Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med. 2006; 259: 259–66
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937–52
   PubMed Web of Science ®Google Scholar
• Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five- year follow-up of men in the Québec Cardiovascular Study. Circulation. 1996; 94: 273–8
   PubMed Web of Science ®Google Scholar
• Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005; 28: 1916–21
   PubMed Web of Science ®Google Scholar
• Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2007; 112: 3375–83
   Google Scholar
• Sniderman AD, Furberg CD, Keech A. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet. 2003; 361: 777–80
   PubMed Web of Science ®Google Scholar
• Sniderman AD. Report of the Thirty Person/Ten Country Panel. ApoB versus Cholesterol to Estimate Cardiovascular Risk and to Guide Therapy. J Intern Med. 2006; 259: 247–58
   Google Scholar
• Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol. 2002; 22: 1918–23
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J Intern Med. 2006; 259: 493–519
   PubMed Web of Science ®Google Scholar
• Gotto AM, Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000; 101: 477–84
   PubMed Web of Science ®Google Scholar
• Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RAH, et al. Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels?. Circulation. 2002; 105: 1162–9
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Collins D, Cupples A, Demissie S, Horvath KV, Bloomfield HE, et al. Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005; 25: 2185–91
   PubMed Web of Science ®Google Scholar
• Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins. An idea whose time for testing is coming. Part I. Circulation. 2001; 104: 2376–83
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. Design and baseline characteristics of the incremental decrease in end points through aggressive lipid lowering study. Am J Cardiol. 2004; 94: 720–4
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: A randomized controlled trial. JAMA. 2005; 294: 2437–45
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded endpoint (PROBE) study: a novel design for intervention trials. Blood Press. 1992; 1: 113–9
   PubMedGoogle Scholar
• Friedewald WT, Levy EI, Fredrichson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of International Reference Material. Clin Chem. 1993; 39: 773–81
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem. 1994; 40: 586–92
   PubMed Web of Science ®Google Scholar
• Hanley JA. Receiver Operating Characteristic (ROC) Curves. Encyclopedia of Biostatistics, P Armitage, T. Colton. Wiley, Chichester 1998; 3738–45
   Google Scholar
• Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007; 298: 776–85
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB Sr, D'Agostino RB, Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72.
   PubMed Web of Science ®Google Scholar
• Stensvold I, Urdal P, Thurmer H, Tverdal A, Lund-Larsen PG, Foss OP. High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women. Eur Heart J. 1992; 13: 1155–63
   PubMed Web of Science ®Google Scholar
• Holme I, Hostmark AT, Anderssen SA. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study. J Int Med. 2007; 262: 235–43
   PubMed Web of Science ®Google Scholar
• Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jiminez F, Walldius G, Hamsten A, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J. 2007; 28: 2637–43
   PubMed Web of Science ®Google Scholar